THE 60-SECOND GUIDE
CJC + Ipamorelin
Combination: controlled human benefit not established.
Guide prepared November 13, 2026 · profile review dates retained
What is it?
CJC-1295 and ipamorelin stimulate growth-hormone signaling through different receptors. Their pairing is an unapproved combination; a change in hormone levels does not establish better recovery, body composition or health. [1]
Potential benefits
Both can stimulate the growth-hormone/IGF-1 axis through different receptors. Small studies established pharmacodynamic activity for CJC-1295. A biologic response does not establish anti-aging, recovery, or body-composition benefit. [1]
Evidence & its limits
Evidence for each ingredient’s hormone response does not establish the combined product’s clinical benefit or long-term safety. CJC-1295 identity also matters: results for the studied long-acting compound cannot simply be assigned to products sold under loosely related names. [1]
Risks & unknowns
The combination lacks FDA approval and robust controlled outcome trials. GH/IGF-1 stimulation may relate to edema, joint symptoms, glucose changes, or other risks. Combined long-term safety, optimal formulation, and product quality remain uncertain; both are prohibited in sport. [1]
Status & scope
Their pairing is an unapproved combination; a change in hormone levels does not establish better recovery, body composition or health. The combination lacks FDA approval and robust controlled outcome trials. [1]
The question to ask
Does the evidence match the exact product, route, condition and outcome being discussed? Check the full record and its review dates. This summary is selective; the product label and clinical assessment contain additional warnings and contraindications.
CHECK THE RECORD
Sources & review
- Full evidence record, references and review dates
- Ipamorelin 1998 paper
- CJC-1295 human study
- WADA prohibited list
Guide prepared November 13, 2026 · profile review dates retained. Condensed from the linked site evidence record. This format update is not a new clinical review of every source. Consult the full profile for its evidence-review dates and targeted updates.
Selective educational summary, not treatment or dosing advice. Existing profile review dates retained; no independent clinical review.